Ovarian Cancer Diagnosis and Treatment

被引:65
作者
Burges, Alexander [1 ]
Schmalfeldt, Barbara [2 ]
机构
[1] Klin & Poliklin Frauenheilkunde & Geburtshilfe Gr, Grosshansdorf, Germany
[2] Frauenklin TU Munchen, Klinikum Rechts Isar, Munich, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2011年 / 108卷 / 38期
关键词
REDUCING SALPINGO-OOPHORECTOMY; PROPHYLACTIC OOPHORECTOMY; SURVIVAL; CHEMOTHERAPY; CARCINOMA; WOMEN; CYTOREDUCTION; MULTICENTER; DISEASE; SURGERY;
D O I
10.3238/arztebl.2011.0635
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with ovarian cancer usually present to a family physician with nonspecific symptoms, most often abdominal pain. The outcome depends above all on the stage of the disease when it is diagnosed and on the quality of treatment. Methods: This article is based on a review of selected publications from 2000 to 2010 that were retrieved by an automated search in Medline on the terms "ovarian cancer," "screening," "diagnosis," "treatment,"and "prognosis," as well as the interdisciplinary S2k guideline Diagnostik und Therapie maligner Ovarialtumoren (the diagnosis and treatment of malignant ovarian tumors) issued in 2007 by the Ovarian Tumor Committee of the German Consortium of Gynecologic Oncology (AGO) and the Committee's updated recommendations of 2009. Results: The proper treatment of early ovarian cancer involves resection of the primary tumor and all macroscopically visible tumor mass as well as meticulous inspection of the entire abdominal cavity for staging. Platinum-based chemotherapy is indicated for women with ovarian cancer in FIGO stage I to IIA (except stage IA, G1). For women with advanced ovarian cancer, the prognosis largely depends on the extent of tumor mass reduction on initial surgery. Complete resection confers significantly longer survival (median 5 years) than incomplete resection. After sur gery, the standard adjuvant chemotherapy consists of a combination of carboplatin and paclitaxel. Treatment that conforms to published guidelines significantly improves survival (60% versus 25% at 3 years). Conclusion: The possibility of ovarian cancer must be considered for any woman who presents with new, persistent, nonspecific abdominal pain. Ovarian cancer should always be treated in accordance with published guidelines.
引用
收藏
页码:635 / 641
页数:7
相关论文
共 24 条
[1]   Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer [J].
Aletti, GD ;
Dowdy, SC ;
Podratz, KC ;
Cliby, WA .
GYNECOLOGIC ONCOLOGY, 2006, 100 (02) :283-287
[2]  
[Anonymous], KREBS DEUTSCHL 2003
[3]  
Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1
[4]   Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer [J].
Bristow, RE ;
Montz, FJ ;
Lagasse, LD ;
Leuchter, RS ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 1999, 72 (03) :278-287
[5]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[6]   Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations [J].
Casey, MJ ;
Synder, C ;
Bewtra, C ;
Narod, SA ;
Watson, P ;
Lynch, HT .
GYNECOLOGIC ONCOLOGY, 2005, 97 (02) :457-467
[7]   Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer [J].
Covens, A ;
Carey, M ;
Bryson, P ;
Verma, S ;
Fung, MFK ;
Johnston, M .
GYNECOLOGIC ONCOLOGY, 2002, 85 (01) :71-80
[8]   Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma [J].
Dowdy, Sean C. ;
Loewen, Ralitsa T. ;
Aletti, Giovanni ;
Feitoza, Simone S. ;
Cliby, William .
GYNECOLOGIC ONCOLOGY, 2008, 109 (02) :303-307
[9]   Borderline Tumors of the Ovary - A Systematic Review [J].
du Bois, A. ;
Ewald-Riegler, N. ;
du Bois, O. ;
Harter, P. .
GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (09) :807-833
[10]  
du Bois A, 2005, FRAUENARZT, V46, P60